<DOC>
	<DOCNO>NCT01440166</DOCNO>
	<brief_summary>- To evaluate safety tolerability escalate single dos CAT-1004 relative placebo healthy adult volunteer . - To evaluate pharmacokinetics ( PK ) escalate single dos CAT-1004 healthy adult volunteer . - To evaluate effect high-fat meal single dose CAT-1004 healthy adult volunteer .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic Study CAT-1004 Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<criteria>Key 1 . In good health . 2 . Age : 19 55 year inclusive Screening . 3 . Satisfies one follow Females childbearing potential : nonpregnant nonlactating ; surgically sterile postmenopausal , OR Males : surgically sterile , abstinent , subject partner utilize acceptable contraceptive method 3 month last study dose . 4 . BMI : 18 30 kg/m2 Screening . Key 1 . Clinically significant abnormality physical examination vital sign . 2 . Clinically significant electrocardiogram ( ECG ) abnormality assess investigator . 3 . Clinically significant screen laboratory result assess Investigator . 4 . The subject history clinically significant allergy ( except untreated , asymptomatic seasonal allergy time dose ) , hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease . 5 . History presence malignancy past 5 year . 6 . History alcohol substance abuse eat disorder within 2 year , OR regular use alcohol within 6 month ( &gt; 14 unit alcohol per week ; 1 unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ) . 7 . Use investigational drug participation investigational study within 30 day prior screen . For dose level 6 7 fed cohort , subject may participate take part dose level 4 5 fasted cohort . 8 . Any significant blood loss within 60 day prior screen , e.g . blood donation , participation study multiple blood draw , etc . 9 . Any condition , disease , disorder clinically relevant laboratory abnormality , opinion Investigator , would jeopardize subject 's appropriate participation study obscure effect treatment . 10 . A suspected allergy sensitivity CAT1004 excipients base upon know allergy excipients compound similar class . 11 . Any clinically significant systemic infection within 3 week prior screen . 12 . Use prescription medication within 30 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Human healthy volunteer</keyword>
</DOC>